Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results
Omnicell (NASDAQ:OMCL) reported strong Q4 2024 financial results, with total revenues of $307 million, up 19% from Q4 2023. However, full-year 2024 revenues decreased 3% to $1.112 billion compared to 2023.
The company achieved GAAP net income of $16 million ($0.34 per diluted share) in Q4 2024, compared to a loss of $14 million in Q4 2023. Full-year 2024 GAAP net income was $13 million ($0.27 per diluted share).
Total bookings for 2024 reached $923 million, an 8% increase from 2023, driven by XT Series upgrades. The company's balance sheet showed $369 million in cash and cash equivalents, with total debt of $341 million. Omnicell issued $172.5 million in convertible senior notes and provided 2025 guidance projecting total revenues between $1.105-1.155 billion.
Omnicell (NASDAQ:OMCL) ha riportato forti risultati finanziari per il quarto trimestre del 2024, con ricavi totali di 307 milioni di dollari, in aumento del 19% rispetto al quarto trimestre del 2023. Tuttavia, i ricavi dell'intero anno 2024 sono diminuiti del 3%, arrivando a 1,112 miliardi di dollari rispetto al 2023.
L'azienda ha raggiunto un reddito netto GAAP di 16 milioni di dollari (0,34 dollari per azione diluita) nel quarto trimestre del 2024, rispetto a una perdita di 14 milioni di dollari nel quarto trimestre del 2023. Il reddito netto GAAP per l'intero anno 2024 è stato di 13 milioni di dollari (0,27 dollari per azione diluita).
Le prenotazioni totali per il 2024 hanno raggiunto 923 milioni di dollari, un aumento dell'8% rispetto al 2023, trainato dagli aggiornamenti della serie XT. Il bilancio dell'azienda mostrava 369 milioni di dollari in contante e equivalenti, con un debito totale di 341 milioni di dollari. Omnicell ha emesso note senior convertibili per un valore di 172,5 milioni di dollari e ha fornito una guida per il 2025 prevedendo ricavi totali tra 1,105 e 1,155 miliardi di dollari.
Omnicell (NASDAQ:OMCL) reportó resultados financieros sólidos en el cuarto trimestre de 2024, con ingresos totales de 307 millones de dólares, un aumento del 19% en comparación con el cuarto trimestre de 2023. Sin embargo, los ingresos del año completo 2024 disminuyeron un 3% a 1,112 mil millones de dólares en comparación con 2023.
La empresa logró un ingreso neto GAAP de 16 millones de dólares (0,34 dólares por acción diluida) en el cuarto trimestre de 2024, en comparación con una pérdida de 14 millones de dólares en el cuarto trimestre de 2023. El ingreso neto GAAP para el año completo 2024 fue de 13 millones de dólares (0,27 dólares por acción diluida).
Las reservas totales para 2024 alcanzaron los 923 millones de dólares, un aumento del 8% en comparación con 2023, impulsadas por las actualizaciones de la serie XT. El balance de la compañía mostró 369 millones de dólares en efectivo y equivalentes, con una deuda total de 341 millones de dólares. Omnicell emitió 172,5 millones de dólares en notas senior convertibles y proporcionó orientación para 2025 proyectando ingresos totales entre 1,105 y 1,155 mil millones de dólares.
Omnicell (NASDAQ:OMCL)는 2024년 4분기 재무 실적이 강력하다고 보고하며 총 수익이 3억 7백만 달러로 2023년 4분기 대비 19% 증가했다고 발표했습니다. 그러나 2024년 전체 수익은 2023년 대비 3% 감소한 11억 1천만 달러에 달했습니다.
회사는 2024년 4분기 GAAP 순이익을 1천6백만 달러(희석 주당 0.34 달러)로 기록한 반면, 2023년 4분기에는 1천4백만 달러의 손실을 보였습니다. 2024년 전체 GAAP 순이익은 1천3백만 달러(희석 주당 0.27 달러)였습니다.
2024년 총 예약은 9억 2천3백만 달러에 달하며, 2023년 대비 8% 증가하였고 XT 시리즈의 업그레이드에 의해 이끌어졌습니다. 회사의 대차대조표는 3억 6천9백만 달러의 현금과 현금성 자산을 보여주었으며, 총 부채는 3억 4천1백만 달러였습니다. Omnicell은 1억 7천2백5십만 달러의 전환 가능한 선순위 채권을 발행하고 2025년 지침을 제공하여 총 수익을 11억 5천만 달러에서 11억 5천5십만 달러 사이로 예측했습니다.
Omnicell (NASDAQ:OMCL) a annoncé de solides résultats financiers pour le quatrième trimestre de 2024, avec des revenus totaux de 307 millions de dollars, soit une augmentation de 19 % par rapport au quatrième trimestre de 2023. Cependant, les revenus de l'année entière 2024 ont diminué de 3 % pour atteindre 1,112 milliard de dollars par rapport à 2023.
L'entreprise a réalisé un résultat net GAAP de 16 millions de dollars (0,34 dollar par action diluée) au quatrième trimestre 2024, comparé à une perte de 14 millions de dollars au quatrième trimestre 2023. Le résultat net GAAP pour l'année entière 2024 était de 13 millions de dollars (0,27 dollar par action diluée).
Les réservations totales pour 2024 ont atteint 923 millions de dollars, soit une augmentation de 8 % par rapport à 2023, grâce aux mises à niveau de la série XT. Le bilan de l'entreprise affichait 369 millions de dollars en espèces et équivalents, avec une dette totale de 341 millions de dollars. Omnicell a émis des obligations senior convertibles d'un montant de 172,5 millions de dollars et a fourni des prévisions pour 2025 anticipant des revenus totaux compris entre 1,105 et 1,155 milliard de dollars.
Omnicell (NASDAQ:OMCL) hat im vierten Quartal 2024 starke Finanzzahlen veröffentlicht, mit Gesamteinnahmen von 307 Millionen Dollar, was einem Anstieg von 19 % im Vergleich zum vierten Quartal 2023 entspricht. Die Gesamteinnahmen für das Jahr 2024 sanken jedoch um 3 % auf 1,112 Milliarden Dollar im Vergleich zu 2023.
Das Unternehmen erzielte im vierten Quartal 2024 einen GAAP-Nettoertrag von 16 Millionen Dollar (0,34 Dollar pro verwässerter Aktie), verglichen mit einem Verlust von 14 Millionen Dollar im vierten Quartal 2023. Der GAAP-Nettoertrag für das gesamte Jahr 2024 betrug 13 Millionen Dollar (0,27 Dollar pro verwässerter Aktie).
Die Gesamtbuchungen für 2024 beliefen sich auf 923 Millionen Dollar, ein Anstieg von 8 % im Vergleich zu 2023, angetrieben durch Upgrades der XT-Serie. Die Bilanz des Unternehmens wies 369 Millionen Dollar in Bargeld und Zahlungsmitteläquivalenten auf, bei einer Gesamtverschuldung von 341 Millionen Dollar. Omnicell emittierte konvertierbare vorrangige Anleihen im Wert von 172,5 Millionen Dollar und gab eine Prognose für 2025 ab, die Gesamteinnahmen zwischen 1,105 und 1,155 Milliarden Dollar erwarten lässt.
- Q4 2024 revenues increased 19% year-over-year to $307 million
- Turned GAAP net loss to profit in Q4 2024 ($16 million vs -$14 million in Q4 2023)
- Total bookings grew 8% year-over-year to $923 million in 2024
- Strong cash position with $369 million in cash and cash equivalents
- Full-year 2024 revenues declined 3% to $1.112 billion
- Non-GAAP net income per share decreased to $1.71 in 2024 from $1.91 in 2023
- Non-GAAP EBITDA slightly decreased to $136 million in 2024 from $138 million in 2023
Insights
Omnicell's Q4 2024 performance marks a pivotal turnaround, with several key indicators suggesting improved business fundamentals. The
The company's financial position has been strategically strengthened through the recent debt restructuring, replacing higher-cost debt with
The introduction of OmniSphere represents a strategic pivot toward cloud-native solutions, positioning Omnicell at the forefront of healthcare technology transformation. This platform's potential to drive recurring revenue growth is reflected in the robust ARR of
The 2025 guidance suggests management's confidence in sustained growth, with projected revenues of
Omnicell delivers strong fourth quarter financial results
Results exceed previously issued full year guidance for bookings, total revenues, and non-GAAP EBITDA
“We delivered solid financial results for the fourth quarter of 2024, including returning to year-over-year revenue growth. We are pleased with the improved execution of the business throughout 2024, including strong free cash flows achieved in the year,” stated Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. “As we progress through 2025, we remain focused on successfully executing on our strategic priorities, which include driving long-term revenue growth, achieving consistent GAAP profitability, and continuing to raise the bar in medication management and adherence through innovation and bringing new products and services to market.”
Financial Results
Total revenues for the fourth quarter of 2024 were
Total GAAP net income for the fourth quarter of 2024 was
Total non-GAAP net income for the fourth quarter of 2024 was
Total non-GAAP EBITDA for the fourth quarter of 2024 was
Bookings and Backlog - Historical Metric
Total bookings(1) for the year ended December 31, 2024 were
The chart below summarizes our total backlog(2) under the definition of bookings in use for the years ended December 31, 2024 and 2023:
|
December 31, |
|||||||
|
2024 |
|
2023 |
|||||
|
(In thousands) |
|||||||
Total backlog |
$ |
1,201,296 |
|
|
$ |
1,142,686 |
|
|
By type: |
|
|
|
|||||
Product backlog |
$ |
646,508 |
|
|
$ |
610,832 |
|
|
SaaS and Expert Services backlog (3) |
$ |
554,788 |
|
|
$ |
531,854 |
|
|
By duration and type: |
|
|
|
|||||
Short-term product backlog |
$ |
447,412 |
|
|
$ |
377,936 |
|
|
Long-term product backlog |
$ |
199,096 |
|
|
$ |
232,896 |
|
|
Short-term SaaS and Expert Services backlog (3) |
$ |
93,113 |
|
|
$ |
72,455 |
|
|
Long-term SaaS and Expert Services backlog (3) |
$ |
461,675 |
|
|
$ |
459,399 |
|
|
|
|
|
|
|||||
| ____________________________ | ||
(1) |
We utilize bookings as an indicator of the success of our business. During 2024, we defined bookings generally as: (i) the value of non-cancelable contracts for our connected devices, software products, and SaaS and Expert Services (although, for those SaaS and Expert Services contracts without a minimum commitment, bookings only include the amount of revenue that has been recognized once the services have been provided); and (ii) for our consumables, the value of orders placed through our Omnicell Storefront online platform or through written or telephonic orders. We typically exclude technical services and other less significant items ancillary to our products and services, such as freight revenue, from bookings. In addition, dependent upon counterparty or credit risk, which is evaluated at the time of contract signing, for a given multi-year subscription contract we may reduce the portion of the contractual commitment booked at a given time. Connected devices and software license bookings are recorded as revenue upon customer acceptance of the installation or receipt of goods. Revenues from SaaS and Expert Services bookings are recorded over the contractual term. |
|
(2) |
Backlog is the dollar amount of bookings that have not yet been recognized as revenue. Bookings for those SaaS and Expert Services contracts without a minimum commitment are not included in backlog. In addition, dependent upon counterparty or credit risk, which is evaluated at the time of contract signing, for a given multi-year subscription contract we may reduce the portion of the contractual commitment booked at a given time, and these excluded amounts are not included in backlog. A majority of our connected devices and software license products are installable and recognized as revenues within twelve months of booking, while service revenues from SaaS and Expert Services are recorded over the contractual term. Larger or more complex implementations such as software-enabled connected devices for Central Pharmacy, including but not limited to our Central Pharmacy Dispensing Service and IV Compounding Service, are often installed and recognized as revenue between 12 and 24 months after booking. We consider backlog that is expected to be converted to revenues in more than twelve months to be long-term backlog. We believe a majority of long-term product backlog will be convertible into revenues in 12 to 24 months. Long-term SaaS and Expert Services backlog typically represents multi-year subscription agreements (usually with contractual terms of 2 to 7 years, some of which have not yet been implemented) that will be converted to revenue over the contractual term. Due to industry practice that allows customers to change order configurations with limited advance notice prior to shipment and as customer installation schedules may change, backlog as of any particular date may not necessarily indicate the timing of future revenue. However, we do believe that backlog is an indication of a customer’s willingness to install our solutions and revenue we expect to generate over time. |
|
(3) |
Includes only the value of SaaS and Expert Services non-cancelable contracts with minimum commitments. |
|
Product Bookings, Product Backlog and Annual Recurring Revenue - New Metrics
Starting in 2025, we will utilize product bookings(1) as a key performance metric for our business. Under the new definition, product bookings as of December 31, 2024 were
|
|
December 31, |
||
|
|
2024 |
||
|
|
|
||
|
|
(In thousands) |
||
Total product backlog(2) |
|
$ |
646,440 |
|
By duration: |
|
|
||
Short-term product backlog |
|
$ |
447,344 |
|
Long-term product backlog |
|
|
199,096 |
|
|
|
|
||
Annual Recurring Revenue(3) |
|
$ |
580,025 |
|
| ____________________________ | ||
(1) |
We define product bookings generally as the value of non-cancelable contracts for our connected devices and software licenses. We typically exclude freight revenue and other less significant items ancillary to our products from product bookings. In addition, dependent upon counterparty or credit risk, which is evaluated at the time of contract signing, for a given multi-year subscription contract we may reduce the value of the contractual commitment booked at a given time. Connected devices and software license bookings are recorded as revenue upon customer acceptance of the installation or receipt of goods. We utilize product bookings as an indicator of the success of certain portions of our business that generate non-recurring revenue. |
|
(2) |
Product backlog is the dollar amount of product bookings that have not yet been recognized as revenue. A majority of our connected devices and software license products are installable and recognized as revenues within twelve months of booking. Larger or more complex implementations such as software-enabled connected devices for Central Pharmacy, including, but not limited to, our Central Pharmacy Dispensing Service and IV Compounding Service, are often installed and recognized as revenue between 12 and 24 months after booking. Due to industry practice that allows customers to change order configurations with limited advance notice prior to shipment and as customer installation schedules may change, backlog as of any particular date may not necessarily indicate the timing of future revenue. However, we do believe that backlog is an indication of a customer’s willingness to install our solutions and revenue we expect to generate over time. We consider backlog that is expected to be converted to revenues in more than twelve months to be long-term backlog. We believe a majority of long-term product backlog will be convertible into revenues in 12-24 months. |
|
(3) |
We consider revenues generated from our consumables, technical services, and SaaS and Expert Services to be recurring revenues. For the portions of our business which generate recurring revenues, we utilize ARR as a key metric to measure our progress in growing our recurring revenue business. We define ARR at a measurement date as the revenue we expect to receive from our customers over the course of the following year for providing them with products or services. ARR includes expected revenue from all customers who are using our products or services at the reported date. For technical services and SaaS and Expert Services, solutions are generally on a contractual basis, typically with contracts for a period of 12 months or more, with a high probability of renewal. Probability of renewal is based on historic renewal experience of the individual revenue streams or management’s best estimates if historical renewal experience is not available. Consumables orders are placed by customers through our Omnicell Storefront online platform or through written or telephonic orders and are sold to a customer base who utilize the consumable product and place recurring orders when customer inventory is depleted. ARR is generally calculated based on revenues received in the most recent quarter and changes to expected revenues where solutions were added to or removed from the install or customer base in the quarter. Revenues from technical services and SaaS and Expert Services are recorded ratably over the service term. Revenue from consumables are recorded when the product has shipped and title has passed. Our measure of ARR may be different than that used by other companies. Because ARR is based on expected future revenue, it does not represent revenue recognized during a particular reporting period or revenue to be recognized in future reporting periods. ARR should not be viewed as a substitute for GAAP revenues. |
|
Balance Sheet
As of December 31, 2024, Omnicell’s balance sheet reflected cash and cash equivalents of
As of December 31, 2024, the Company had
Business Highlights
OmniSphere
The Company announced OmniSphere, a next-generation, cloud native, software workflow engine and data platform that is intended to seamlessly integrate enterprise-wide robotics and smart devices to support more secure, data-driven, medication management across the continuum of care. OmniSphere is designed to provide customers state-of-the-art security, improved productivity, enterprise-wide visibility, and streamlined upgrades, that is meant to deliver optimal end-to-end medication management.
ASHP Midyear
More than 1,600 pharmacy and industry leaders had the opportunity to explore Omnicell’s portfolio of outcomes-centric solutions and learn best practices from peers as part of the American Society of Health System Pharmacists (ASHP) Midyear 2024 Clinical Meeting and Exhibition. This annual event is the largest gathering of pharmacy professionals in the world.
HITRUST Data Security Certification
Omnicell’s medication management solutions powered by the OmniCenter platform once again received HITRUST Common Security Framework (CSF) certification, which we believe demonstrates the Company’s ongoing commitment to high standards for cybersecurity and data protection within the organization and for business partners and customers.
Omnicell Issues New Convertible Senior Notes
In late November, Omnicell issued
2025 Guidance
The table below summarizes Omnicell’s first quarter and full year 2025 guidance:
|
Q1 2025 |
|
2025 |
|
Product Bookings (2025 Definition) |
Not provided |
|
|
|
ARR |
Not Provided |
|
|
|
Total Revenues |
|
|
|
|
Product Revenues |
|
|
|
|
Service Revenues |
|
|
|
|
Technical Services Revenues |
Not provided |
|
|
|
SaaS and Expert Service Revenue (formerly Advanced Services) |
Not provided |
|
|
|
Non-GAAP EBITDA |
|
|
|
|
Non-GAAP Earnings Per Share |
|
|
|
The Company does not provide guidance for GAAP net income or GAAP earnings per share, nor a reconciliation of any forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures on a forward-looking basis because it is unable to predict certain items contained in the GAAP measures without unreasonable efforts. These forward-looking non-GAAP financial measures do not include certain items, which may be significant, including, but not limited to, unusual gains and losses, costs associated with future restructurings, acquisition-related expenses, and certain tax and litigation outcomes.
Omnicell Conference Call Information
Omnicell will hold a conference call today, Thursday, February 6, 2025 at 8:30 a.m. ET to discuss fourth quarter and year end 2024 financial results. The conference call can be monitored by dialing (800) 715-9871 in the
About Omnicell
Since 1992, Omnicell has been committed to transforming pharmacy and nursing care through outcomes-centric solutions designed to deliver clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics and smart devices, intelligent software workflows, and data and analytics, all optimized by expert services, Omnicell solutions are helping healthcare facilities worldwide to uncover cost savings, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry-defined vision of the Autonomous Pharmacy. To learn more, visit omnicell.com.
From time to time, Omnicell may use the Company’s investor relations website and other online social media channels, including its LinkedIn page www.linkedin.com/company/omnicell, and Facebook page www.facebook.com/omnicellinc, to disclose material non-public information and comply with its disclosure obligations under Regulation Fair Disclosure (“Reg FD”).
OMNICELL, the Omnicell logo, and ENLIVENHEALTH are registered trademarks of Omnicell, Inc. or one of its subsidiaries. This press release may also include the trademarks and service marks of other companies. Such trademarks and service marks are the marks of their respective owners.
Forward-Looking Statements
To the extent any statements contained in this press release deal with information that is not historical, these statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seek,” “predict,” “project,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control. Such statements include, but are not limited to, Omnicell’s projected product bookings, revenues, including product, service, technical services and SaaS and Expert Services revenues, annual recurring revenue, non-GAAP EBITDA, and non-GAAP earnings per share; expectations regarding our products and services and developing new or enhancing existing products and solutions and the related objectives and expected benefits (and any implied financial impact); our ability to drive long-term growth and consistent GAAP profitability; and statements about Omnicell’s strategy, plans, objectives, promise and purpose, goals, opportunities, and market or Company outlook. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) unfavorable general economic and market conditions, including the impact and duration of inflationary pressures, (ii) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (iv) delays in installations of our medication management solutions or our more complex medication packaging systems, (v) risks related to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, and its ability to acquire companies, businesses, or technologies and successfully integrate such acquisitions, (vi) ability to realize the benefits of our expense containment initiatives, (vii) risks related to failing to maintain expected service levels when providing our SaaS and Expert Services or retaining our SaaS and Expert Services customers, (viii) Omnicell’s ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (ix) risks related to climate change, legal, regulatory or market measures to address climate change and related emphasis on ESG matters by various stakeholders, (x) changes to the 340B Program, (xi) risks related to the incorporation of artificial intelligence technologies into our products, services and processes or our vendors' offerings, (xii) Omnicell’s substantial debt, which could impair its financial flexibility and access to capital, (xiii) covenants in our credit agreement could restrict our business and operations, (xiv) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (xv) risks presented by government regulations, legislative changes, fraud and anti-kickback statues, products liability claims, the outcome of legal proceedings, and other legal obligations related to healthcare, privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations, including any potential governmental investigations and enforcement actions, litigation, fines and penalties, exposure to indemnification obligations or other liabilities, and adverse publicity related to the same; (xvi) any disruption in Omnicell’s information technology systems and breaches of data security or cyber-attacks on its systems or solutions, including the previously disclosed ransomware incident and any potential adverse legal, reputational, and financial effects that may result from it and/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, (xvii) risks associated with operating in foreign countries, (xviii) Omnicell’s ability to recruit and retain skilled and motivated personnel, (xix) Omnicell’s ability to protect its intellectual property, (xx) risks related to the availability and sources of raw materials and components or price fluctuations, shortages, or interruptions of supply, (xxi) Omnicell’s dependence on a limited number of suppliers for certain components, equipment, and raw materials, as well as technologies provided by third-party vendors, (xxii) fluctuations in quarterly and annual operating results may make our future operating results difficult to predict, (xxiii) failing to meet (or significantly exceeding) our publicly announced financial guidance, and (xxiv) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.
Use of Non-GAAP Financial Information
This press release contains financial measures that are not calculated in accordance with
Our non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP EBITDA, and non-GAAP EBITDA margin are exclusive of certain items to facilitate management’s review of the comparability of Omnicell’s core operating results on a period-to-period basis because such items are not related to Omnicell’s ongoing core operating results as viewed by management. We define our “core operating results” as those revenues recorded in a particular period and the expenses incurred within such period that directly drive operating income in such period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operating performance, the measures give us a better understanding of how we believe we should invest in research and development, fund infrastructure growth, and evaluate the effectiveness of marketing strategies. In calculating the above non-GAAP results: non-GAAP gross profit and non-GAAP gross margin exclude from their GAAP equivalents items a), b), e), and g) below; non-GAAP operating expenses excludes from its GAAP equivalents items a), b), c), d), e), g), h), i), j) and k) below; non-GAAP income from operations and non-GAAP operating margin exclude from their GAAP equivalents items a), b), c), d), e), g), h),i), j) and k) below; and non-GAAP net income and non-GAAP net income per diluted share exclude from their GAAP equivalents items a) through l) below. Non-GAAP EBITDA is defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. Non-GAAP EBITDA and non-GAAP EBITDA margin exclude from their GAAP equivalents items a), c), d), e), f), g), h), i), j), k) and l) below:
a) |
Share-based compensation expense. We excluded from our non-GAAP results the expense related to equity-based compensation plans as it represents expenses that do not require cash settlement from Omnicell. |
|
|
|
|
b) |
Amortization of acquired intangible assets. We excluded from our non-GAAP results the intangible assets amortization expense resulting from our past acquisitions. These non-cash charges are not considered by management to reflect the core cash-generating performance of the business and therefore are excluded from our non-GAAP results. |
|
|
|
|
c) |
Acquisition-related expenses. We excluded from our non-GAAP results the expenses related to recent acquisitions, including amortization of representations and warranties insurance. These expenses are unrelated to our ongoing operations, vary in size and frequency, and are subject to significant fluctuations from period to period due to varying levels of acquisition activity. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies. |
|
|
|
|
d) |
Impairment and abandonment of operating lease right-of-use and other assets related to facilities. We excluded from our non-GAAP results the impairment and abandonment of certain operating lease right-of-use assets, as well as property and equipment, incurred in connection with restructuring activities for optimization of certain leased facilities. These non-cash charges are not considered by management to reflect the core cash-generating performance of the business and therefore are excluded from our non-GAAP results. |
|
|
|
|
e) |
Severance-related expenses. We excluded from our non-GAAP results the expenses related to restructuring events, partially offset by reversals of previously recognized severance expenses in subsequent periods. These expenses are unrelated to our ongoing operations, vary in size and frequency, and are subject to significant fluctuations from period to period due to varying levels of restructuring activity. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies. |
|
|
|
|
f) |
Amortization of debt issuance costs. Debt issuance costs represent costs associated with the issuance of revolving credit facilities and convertible senior notes. The costs include underwriting fees, original issue discount, ticking fees, and legal fees. These non-cash expenses are not considered by management to reflect the core cash-generating performance of the business and therefore are excluded from our non-GAAP results. |
|
|
|
|
g) |
RDS restructuring. We excluded from our non-GAAP results the nonrecurring restructuring charges related to the wind down of the Company’s Medimat Robotic Dispensing System (“RDS”) product line, partially offset by reversals of previously recognized expenses in subsequent periods. For the period ended December 31, 2024, those charges consisted primarily of inventory write-down, severance and other related expenses. These expenses are unrelated to our ongoing operations and we believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies. |
|
|
|
|
h) |
Executives transition costs. We excluded from our non-GAAP results the executives transition costs associated with the departure of certain executive officers, primarily consisting of severance expenses. These expenses are unrelated to our ongoing operations and we do not expect them to occur in the ordinary course of business. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies. |
|
|
|
|
i) |
Ransomware-related insurance recoveries. We excluded from our non-GAAP results the insurance recoveries related to the previously disclosed ransomware incident identified by the Company on May 4, 2022. These recoveries are unrelated to our ongoing operations and would not have otherwise been received by us in the normal course of business. We believe that excluding these recoveries provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies. |
|
|
|
|
j) |
Legal and regulatory expenses. We excluded from our non-GAAP results certain non-recurring legal and regulatory expenses, representing potential settlement amounts, related to certain claims of non-compliance with our government contracts that are outside of the ordinary course of our business. We believe that excluding these amounts provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies. |
|
|
|
|
k) |
Management severance costs. We excluded from our non-GAAP results the severance expense of certain senior management associated with the restructuring of our senior leadership team. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies. |
|
|
|
|
l) |
Gain on extinguishment of convertible senior notes, net. We excluded from our non-GAAP results the gain on the partial repurchase of the Company’s Senior Convertible Notes due 2025 as well as the related unwinding of the convertible note hedge and warrants. We believe that excluding this gain provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies. |
Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is largely outside of Omnicell’s control; they are unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational or non-cash expenses involving stock compensation plans or other items.
We believe that the presentation of non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP EBITDA, and non-GAAP EBITDA margin is warranted for several reasons:
a) |
Such non-GAAP financial measures provide an additional analytical tool for understanding Omnicell’s financial performance by excluding the impact of items which may obscure trends in the core operating results of the business. |
|
|
|
|
b) |
Since we have historically reported non-GAAP results to the investment community, we believe the inclusion of non-GAAP numbers provides consistency and enhances investors’ ability to compare our performance across financial reporting periods. |
|
|
|
|
c) |
These non-GAAP financial measures are employed by management in its own evaluation of performance and are utilized in financial and operational decision-making processes, such as budget planning and forecasting. |
|
|
|
|
d) |
These non-GAAP financial measures facilitate comparisons to the operating results of other companies in our industry, which also use non-GAAP financial measures to supplement their GAAP results (although these companies may calculate non-GAAP financial measures differently than Omnicell does), thus enhancing the perspective of investors who wish to utilize such comparisons in their analysis of our performance. |
Set forth below are additional reasons why share-based compensation expense is excluded from our non-GAAP financial measures:
i) |
While share-based compensation calculated in accordance with Accounting Standards Codification (“ASC”) 718 constitutes an ongoing and recurring expense of Omnicell, it is not an expense that requires cash settlement by Omnicell. We therefore exclude these charges for purposes of evaluating core operating results. Thus, our non-GAAP measurements are presented exclusive of share-based compensation expense to assist management and investors in evaluating our core operating results. |
|
ii) |
We present ASC 718 share-based payment compensation expense in our reconciliation of non-GAAP financial measures on a pre-tax basis because the exact tax differences related to the timing and deductibility of share-based compensation under ASC 718 are dependent upon the trading price of Omnicell’s common stock and the timing and exercise by employees of their stock options. As a result of these timing and market uncertainties, the tax effect related to share-based compensation expense would be inconsistent in amount and frequency and is therefore excluded from our non-GAAP results. |
Non-GAAP diluted shares is defined as our GAAP diluted shares, excluding the impact of dilutive convertible senior notes for which the Company is economically hedged through its anti-dilutive convertible note hedge transaction. We believe non-GAAP diluted shares is a useful non-GAAP metric because it provides insight into the offsetting economic effect of the hedge transaction against potential conversion of the convertible senior notes.
Non-GAAP free cash flow is defined as net cash provided by operating activities less cash used for software development for external use and purchases of property and equipment. We believe free cash flow is important to enable investors to better understand and evaluate our ongoing operating results and allows for greater transparency in the review and understanding of our overall financial, operational, and economic performance, because free cash flow takes into account certain capital expenditures and cash used for software development necessary to operate our business.
As stated above, we present non-GAAP financial measures because we consider them to be important supplemental measures of performance. However, non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for Omnicell’s GAAP results. In the future, we expect to incur expenses similar to certain of the non-GAAP adjustments described above and expect to continue reporting non-GAAP financial measures excluding such items. Some of the limitations in relying on non-GAAP financial measures are:
a) |
Omnicell’s equity incentive plans and stock purchase plans are important components of incentive compensation arrangements and will be reflected as expenses in Omnicell’s GAAP results for the foreseeable future under ASC 718. |
|
b) |
Other companies, including companies in Omnicell’s industry, may calculate non-GAAP financial measures differently than Omnicell, limiting their usefulness as a comparative measure. |
|
c) |
A limitation of the utility of free cash flow as a measure of financial performance is that it does not represent the total increase or decrease in Omnicell’s cash balance for the period. |
A detailed reconciliation between Omnicell’s non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release as well as in Omnicell’s other reports filed with or furnished to the SEC.
Omnicell, Inc. |
||||||||||||||||
Condensed Consolidated Statements of Operations |
||||||||||||||||
(Unaudited, in thousands, except per share data) |
||||||||||||||||
|
|
|
|
|
||||||||||||
|
|
Three Months Ended
|
|
Year Ended
|
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
|
|
|
|
|
|
|
|
|||||||||
Revenues: |
|
|
|
|
|
|
|
|||||||||
Product revenues |
$ |
182,271 |
|
|
$ |
145,655 |
|
|
$ |
630,507 |
|
|
$ |
708,561 |
|
|
Service revenues |
|
124,608 |
|
|
|
113,192 |
|
|
|
481,731 |
|
|
|
438,551 |
|
|
Total revenues |
|
306,879 |
|
|
|
258,847 |
|
|
|
1,112,238 |
|
|
|
1,147,112 |
|
|
Cost of revenues: |
|
|
|
|
|
|
|
|||||||||
Cost of product revenues |
|
96,755 |
|
|
|
90,306 |
|
|
|
383,025 |
|
|
|
414,106 |
|
|
Cost of service revenues |
|
68,363 |
|
|
|
63,137 |
|
|
|
258,210 |
|
|
|
236,166 |
|
|
Total cost of revenues |
|
165,118 |
|
|
|
153,443 |
|
|
|
641,235 |
|
|
|
650,272 |
|
|
Gross profit |
|
141,761 |
|
|
|
105,404 |
|
|
|
471,003 |
|
|
|
496,840 |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|||||||||
Research and development |
|
26,040 |
|
|
|
26,819 |
|
|
|
90,412 |
|
|
|
97,115 |
|
|
Selling, general, and administrative |
|
103,325 |
|
|
|
101,950 |
|
|
|
380,254 |
|
|
|
434,593 |
|
|
Total operating expenses |
|
129,365 |
|
|
|
128,769 |
|
|
|
470,666 |
|
|
|
531,708 |
|
|
Income (loss) from operations |
|
12,396 |
|
|
|
(23,365 |
) |
|
|
337 |
|
|
|
(34,868 |
) |
|
Interest and other income (expense), net |
|
11,204 |
|
|
|
4,848 |
|
|
|
25,256 |
|
|
|
14,760 |
|
|
Income (loss) before income taxes |
|
23,600 |
|
|
|
(18,517 |
) |
|
|
25,593 |
|
|
|
(20,108 |
) |
|
Provision for (benefit from) income taxes |
|
7,758 |
|
|
|
(4,142 |
) |
|
|
13,062 |
|
|
|
263 |
|
|
Net income (loss) |
$ |
15,842 |
|
|
$ |
(14,375 |
) |
|
$ |
12,531 |
|
|
$ |
(20,371 |
) |
|
Net income (loss) per share: |
|
|
|
|
|
|
|
|||||||||
Basic |
$ |
0.34 |
|
|
$ |
(0.32 |
) |
|
$ |
0.27 |
|
|
$ |
(0.45 |
) |
|
Diluted |
$ |
0.34 |
|
|
$ |
(0.32 |
) |
|
$ |
0.27 |
|
|
$ |
(0.45 |
) |
|
Weighted-average shares outstanding: |
|
|
|
|
|
|
|
|||||||||
Basic |
|
46,345 |
|
|
|
45,495 |
|
|
|
46,047 |
|
|
|
45,212 |
|
|
Diluted |
|
46,854 |
|
|
|
45,495 |
|
|
|
46,255 |
|
|
|
45,212 |
|
|
Omnicell, Inc. |
||||||||
Condensed Consolidated Balance Sheets |
||||||||
(Unaudited, in thousands) |
||||||||
|
|
|
||||||
|
|
December 31, |
||||||
|
|
2024 |
|
2023 |
||||
|
|
|
|
|||||
ASSETS |
||||||||
Current assets: |
|
|
|
|||||
Cash and cash equivalents |
$ |
369,201 |
|
|
$ |
467,972 |
|
|
Accounts receivable and unbilled receivables, net |
|
256,398 |
|
|
|
252,025 |
|
|
Inventories |
|
88,659 |
|
|
|
110,099 |
|
|
Prepaid expenses |
|
25,942 |
|
|
|
25,966 |
|
|
Other current assets |
|
75,293 |
|
|
|
71,509 |
|
|
Total current assets |
|
815,493 |
|
|
|
927,571 |
|
|
Property and equipment, net |
|
112,692 |
|
|
|
108,601 |
|
|
Long-term investment in sales-type leases, net |
|
52,744 |
|
|
|
42,954 |
|
|
Operating lease right-of-use assets |
|
25,607 |
|
|
|
24,988 |
|
|
Goodwill |
|
734,727 |
|
|
|
735,810 |
|
|
Intangible assets, net |
|
188,266 |
|
|
|
211,173 |
|
|
Long-term deferred tax assets |
|
57,469 |
|
|
|
32,901 |
|
|
Prepaid commissions |
|
54,656 |
|
|
|
52,414 |
|
|
Other long-term assets |
|
79,306 |
|
|
|
90,466 |
|
|
Total assets |
$ |
2,120,960 |
|
|
$ |
2,226,878 |
|
|
|
|
|
|
|||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
Current liabilities: |
|
|
|
|||||
Accounts payable |
$ |
51,782 |
|
|
$ |
45,028 |
|
|
Accrued compensation |
|
60,307 |
|
|
|
51,754 |
|
|
Accrued liabilities |
|
167,895 |
|
|
|
149,276 |
|
|
Deferred revenues |
|
141,370 |
|
|
|
121,734 |
|
|
Convertible senior notes, net |
|
174,324 |
|
|
|
— |
|
|
Total current liabilities |
|
595,678 |
|
|
|
367,792 |
|
|
Long-term deferred revenues |
|
76,123 |
|
|
|
58,622 |
|
|
Long-term deferred tax liabilities |
|
1,108 |
|
|
|
1,620 |
|
|
Long-term operating lease liabilities |
|
31,123 |
|
|
|
33,910 |
|
|
Other long-term liabilities |
|
7,218 |
|
|
|
6,318 |
|
|
Convertible senior notes, net |
|
166,397 |
|
|
|
569,662 |
|
|
Total liabilities |
|
877,647 |
|
|
|
1,037,924 |
|
|
Total stockholders’ equity |
|
1,243,313 |
|
|
|
1,188,954 |
|
|
Total liabilities and stockholders’ equity |
$ |
2,120,960 |
|
|
$ |
2,226,878 |
|
|
Omnicell, Inc. |
||||||||
Condensed Consolidated Statements of Cash Flows |
||||||||
(Unaudited, in thousands) |
||||||||
|
|
|
||||||
|
|
Year Ended December 31, |
||||||
|
|
2024 |
|
2023 |
||||
Operating Activities |
|
|
|
|||||
Net income (loss) |
$ |
12,531 |
|
|
$ |
(20,371 |
) |
|
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |
|
|
|
|||||
Depreciation and amortization |
|
82,232 |
|
|
|
87,319 |
|
|
Loss on disposal of assets |
|
978 |
|
|
|
2,572 |
|
|
Share-based compensation expense |
|
39,316 |
|
|
|
55,300 |
|
|
Deferred income taxes |
|
(14,855 |
) |
|
|
(11,047 |
) |
|
Amortization of operating lease right-of-use assets |
|
7,523 |
|
|
|
8,239 |
|
|
Impairment and abandonment of operating lease right-of-use assets related to facilities |
|
— |
|
|
|
9,998 |
|
|
Inventory write-down |
|
5,393 |
|
|
|
— |
|
|
Impairment of certain long-lived assets |
|
— |
|
|
|
1,014 |
|
|
Amortization of debt issuance costs |
|
3,788 |
|
|
|
4,397 |
|
|
Gain on extinguishment of convertible senior notes, net |
|
(7,517 |
) |
|
|
— |
|
|
Changes in operating assets and liabilities: |
|
|
|
|||||
Accounts receivable and unbilled receivables |
|
(5,002 |
) |
|
|
49,150 |
|
|
Inventories |
|
15,633 |
|
|
|
38,016 |
|
|
Prepaid expenses |
|
24 |
|
|
|
1,149 |
|
|
Other current assets |
|
9,337 |
|
|
|
(6,821 |
) |
|
Investment in sales-type leases |
|
(10,398 |
) |
|
|
(10,411 |
) |
|
Prepaid commissions |
|
(2,242 |
) |
|
|
7,069 |
|
|
Other long-term assets |
|
2,161 |
|
|
|
2,111 |
|
|
Accounts payable |
|
7,210 |
|
|
|
(17,525 |
) |
|
Accrued compensation |
|
8,553 |
|
|
|
(21,461 |
) |
|
Accrued liabilities |
|
13,942 |
|
|
|
(10,343 |
) |
|
Deferred revenues |
|
28,952 |
|
|
|
24,058 |
|
|
Operating lease liabilities |
|
(10,737 |
) |
|
|
(10,918 |
) |
|
Other long-term liabilities |
|
900 |
|
|
|
(401 |
) |
|
Net cash provided by operating activities |
|
187,722 |
|
|
|
181,094 |
|
|
Investing Activities |
|
|
|
|||||
External-use software development costs |
|
(16,330 |
) |
|
|
(13,542 |
) |
|
Purchases of property and equipment |
|
(36,463 |
) |
|
|
(41,474 |
) |
|
Net cash used in investing activities |
|
(52,793 |
) |
|
|
(55,016 |
) |
|
Financing Activities |
|
|
|
|||||
Payments for debt issuance costs for revolving credit facility |
|
— |
|
|
|
(2,967 |
) |
|
Proceeds from issuance of convertible senior notes, net of issuance costs |
|
166,272 |
|
|
|
— |
|
|
Partial repurchase of convertible senior notes |
|
(391,000 |
) |
|
|
— |
|
|
Purchase of convertible note hedge |
|
(40,279 |
) |
|
|
— |
|
|
Proceeds from sale of warrants |
|
25,168 |
|
|
|
— |
|
|
Partial unwind of convertible note hedge and warrants |
|
(727 |
) |
|
|
— |
|
|
Proceeds from issuances under stock-based compensation plans |
|
13,411 |
|
|
|
23,216 |
|
|
Employees’ taxes paid related to restricted stock units |
|
(4,827 |
) |
|
|
(7,366 |
) |
|
Change in customer funds, net |
|
(3,596 |
) |
|
|
10,537 |
|
|
Net cash provided by (used in) financing activities |
|
(235,578 |
) |
|
|
23,420 |
|
|
Effect of exchange rate changes on cash and cash equivalents |
|
(1,716 |
) |
|
|
(1,354 |
) |
|
Net increase (decrease) in cash, cash equivalents, and restricted cash |
|
(102,365 |
) |
|
|
148,144 |
|
|
Cash, cash equivalents, and restricted cash at beginning of period |
|
500,979 |
|
|
|
352,835 |
|
|
Cash, cash equivalents, and restricted cash at end of period |
$ |
398,614 |
|
|
$ |
500,979 |
|
|
Reconciliation of cash, cash equivalents, and restricted cash to the Condensed Consolidated Balance Sheets: |
|
|
|
|||||
Cash and cash equivalents |
$ |
369,201 |
|
|
$ |
467,972 |
|
|
Restricted cash included in other current assets |
|
29,413 |
|
|
|
33,007 |
|
|
Cash, cash equivalents, and restricted cash at end of period |
$ |
398,614 |
|
|
$ |
500,979 |
|
|
Omnicell, Inc. |
||||||||||||||||
Reconciliation of GAAP to Non-GAAP |
||||||||||||||||
(Unaudited, in thousands, except per share data and percentage) |
||||||||||||||||
|
|
|
|
|
||||||||||||
|
|
Three Months Ended
|
|
Year Ended
|
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Reconciliation of GAAP gross profit to non-GAAP gross profit: |
||||||||||||||||
GAAP gross profit |
$ |
141,761 |
|
$ |
105,404 |
|
$ |
471,003 |
|
$ |
496,840 |
|
||||
GAAP gross margin |
|
46.2 |
% |
|
40.7 |
% |
|
42.3 |
% |
|
43.3 |
% |
||||
Share-based compensation expense |
|
1,489 |
|
|
1,799 |
|
|
6,373 |
|
|
8,288 |
|
||||
Amortization of acquired intangibles |
|
1,017 |
|
|
2,607 |
|
|
4,131 |
|
|
11,165 |
|
||||
RDS restructuring, net of reversals |
|
1,211 |
|
|
— |
|
|
9,897 |
|
|
— |
|
||||
Severance-related expenses, net of reversals |
|
— |
|
|
2,987 |
|
|
— |
|
|
3,089 |
|
||||
Non-GAAP gross profit |
$ |
145,478 |
|
$ |
112,797 |
|
$ |
491,404 |
|
$ |
519,382 |
|
||||
Non-GAAP gross margin |
|
47.4 |
% |
|
43.6 |
% |
|
44.2 |
% |
|
45.3 |
% |
||||
|
|
|
|
|
||||||||||||
Reconciliation of GAAP operating expenses to non-GAAP operating expenses: |
||||||||||||||||
GAAP operating expenses |
$ |
129,365 |
|
$ |
128,769 |
|
$ |
470,666 |
|
$ |
531,708 |
|
||||
GAAP operating expenses % to total revenues |
|
42.2 |
% |
|
49.7 |
% |
|
42.3 |
% |
|
46.4 |
% |
||||
Share-based compensation expense |
|
(7,550 |
) |
|
(10,388 |
) |
|
(32,943 |
) |
|
(47,012 |
) |
||||
Amortization of acquired intangibles |
|
(4,480 |
) |
|
(5,007 |
) |
|
(18,578 |
) |
|
(20,409 |
) |
||||
Acquisition-related expenses |
|
(182 |
) |
|
(244 |
) |
|
(898 |
) |
|
(982 |
) |
||||
Impairment and abandonment of operating lease right-of-use and other assets related to facilities (a) |
|
— |
|
|
(1,587 |
) |
|
— |
|
|
(10,007 |
) |
||||
RDS restructuring, net of reversals |
|
(1,223 |
) |
|
(1,610 |
) |
|
(2,056 |
) |
|
(1,610 |
) |
||||
Ransomware-related insurance recoveries |
|
— |
|
|
624 |
|
|
— |
|
|
808 |
|
||||
Legal and regulatory expenses |
|
(2,000 |
) |
|
— |
|
|
(2,000 |
) |
|
— |
|
||||
Management severance costs |
|
(911 |
) |
|
— |
|
|
(911 |
) |
|
— |
|
||||
Executives transition costs |
|
— |
|
|
— |
|
|
— |
|
|
(2,189 |
) |
||||
Severance-related expenses, net of reversals |
|
— |
|
|
(7,098 |
) |
|
— |
|
|
(12,450 |
) |
||||
Non-GAAP operating expenses |
$ |
113,019 |
|
$ |
103,459 |
|
$ |
413,280 |
|
$ |
437,857 |
|
||||
Non-GAAP operating expenses as a % of total revenues |
|
36.8 |
% |
|
40.0 |
% |
|
37.2 |
% |
|
38.2 |
% |
||||
|
|
|
|
|
||||||||||||
Reconciliation of GAAP income (loss) from operations to non-GAAP income from operations: |
||||||||||||||||
GAAP income (loss) from operations |
$ |
12,396 |
|
$ |
(23,365 |
) |
$ |
337 |
|
$ |
(34,868 |
) |
||||
GAAP operating income (loss) % to total revenues |
|
4.0 |
% |
|
(9.0 |
)% |
|
0.0 |
% |
|
(3.0 |
)% |
||||
Share-based compensation expense |
|
9,039 |
|
|
12,187 |
|
|
39,316 |
|
|
55,300 |
|
||||
Amortization of acquired intangibles |
|
5,497 |
|
|
7,614 |
|
|
22,709 |
|
|
31,574 |
|
||||
Acquisition-related expenses |
|
182 |
|
|
244 |
|
|
898 |
|
|
982 |
|
||||
Impairment and abandonment of operating lease right-of-use and other assets related to facilities (a) |
|
— |
|
|
1,587 |
|
|
— |
|
|
10,007 |
|
||||
RDS restructuring, net of reversals |
|
2,434 |
|
|
1,610 |
|
|
11,953 |
|
|
1,610 |
|
||||
Ransomware-related insurance recoveries |
|
— |
|
|
(624 |
) |
|
— |
|
|
(808 |
) |
||||
Legal and regulatory expenses |
|
2,000 |
|
|
— |
|
|
2,000 |
|
|
— |
|
||||
Management severance costs |
|
911 |
|
|
— |
|
|
911 |
|
|
— |
|
||||
Executives transition costs |
|
— |
|
|
— |
|
|
— |
|
|
2,189 |
|
||||
Severance-related expenses, net of reversals |
|
— |
|
|
10,085 |
|
|
— |
|
|
15,539 |
|
||||
Non-GAAP income from operations |
$ |
32,459 |
|
$ |
9,338 |
|
$ |
78,124 |
|
$ |
81,525 |
|
||||
Non-GAAP operating margin (non-GAAP operating income as a % of total revenues) |
|
10.6 |
% |
|
3.6 |
% |
|
7.0 |
% |
|
7.1 |
% |
||||
Omnicell, Inc. |
||||||||||||||||
Reconciliation of GAAP to Non-GAAP |
||||||||||||||||
(Unaudited, in thousands, except per share data and percentage) |
||||||||||||||||
|
|
|
|
|
||||||||||||
|
|
Three Months Ended
|
|
Year Ended
|
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
|
|
|
|
|
||||||||||||
Reconciliation of GAAP net income (loss) to non-GAAP net income: |
||||||||||||||||
GAAP net income (loss) |
$ |
15,842 |
|
$ |
(14,375 |
) |
$ |
12,531 |
|
$ |
(20,371 |
) |
||||
Share-based compensation expense |
|
9,039 |
|
|
12,187 |
|
|
39,316 |
|
|
55,300 |
|
||||
Amortization of acquired intangibles |
|
5,497 |
|
|
7,614 |
|
|
22,709 |
|
|
31,574 |
|
||||
Acquisition-related expenses |
|
182 |
|
|
244 |
|
|
898 |
|
|
982 |
|
||||
Impairment and abandonment of operating lease right-of-use and other assets related to facilities (a) |
|
— |
|
|
1,587 |
|
|
— |
|
|
10,007 |
|
||||
RDS restructuring, net of reversals |
|
2,434 |
|
|
1,610 |
|
|
11,953 |
|
|
1,610 |
|
||||
Ransomware-related insurance recoveries |
|
— |
|
|
(624 |
) |
|
— |
|
|
(808 |
) |
||||
Legal and regulatory expenses |
|
2,000 |
|
|
— |
|
|
2,000 |
|
|
— |
|
||||
Management severance costs |
|
911 |
|
|
— |
|
|
911 |
|
|
— |
|
||||
Executives transition costs |
|
— |
|
|
— |
|
|
— |
|
|
2,189 |
|
||||
Severance-related expenses, net of reversals |
|
— |
|
|
10,085 |
|
|
— |
|
|
15,539 |
|
||||
Amortization of debt issuance costs |
|
871 |
|
|
1,258 |
|
|
3,788 |
|
|
4,397 |
|
||||
Gain on extinguishment of convertible senior notes, net |
|
(7,517 |
) |
|
— |
|
|
(7,517 |
) |
|
— |
|
||||
Tax effect of the adjustments above (b) |
|
(919 |
) |
|
(4,573 |
) |
|
(7,295 |
) |
|
(13,754 |
) |
||||
Non-GAAP net income |
$ |
28,340 |
|
$ |
15,013 |
|
$ |
79,294 |
|
$ |
86,665 |
|
||||
|
|
|
|
|
||||||||||||
Reconciliation of GAAP net income (loss) per share - diluted to non-GAAP net income per share - diluted: |
||||||||||||||||
Shares - diluted GAAP |
|
46,854 |
|
|
45,495 |
|
|
46,255 |
|
|
45,212 |
|
||||
Shares - diluted non-GAAP |
|
46,854 |
|
|
45,532 |
|
|
46,255 |
|
|
45,439 |
|
||||
|
|
|
|
|
||||||||||||
GAAP net income (loss) per share - diluted |
$ |
0.34 |
|
$ |
(0.32 |
) |
$ |
0.27 |
|
$ |
(0.45 |
) |
||||
Share-based compensation expense |
|
0.19 |
|
|
0.26 |
|
|
0.85 |
|
|
1.22 |
|
||||
Amortization of acquired intangibles |
|
0.12 |
|
|
0.17 |
|
|
0.49 |
|
|
0.69 |
|
||||
Acquisition-related expenses |
|
0.00 |
|
|
0.01 |
|
|
0.02 |
|
|
0.02 |
|
||||
Impairment and abandonment of operating lease right-of-use and other assets related to facilities (a) |
|
— |
|
|
0.03 |
|
|
— |
|
|
0.22 |
|
||||
RDS restructuring, net of reversals |
|
0.05 |
|
|
0.04 |
|
|
0.26 |
|
|
0.04 |
|
||||
Ransomware-related insurance recoveries |
|
— |
|
|
(0.01 |
) |
|
— |
|
|
(0.02 |
) |
||||
Legal and regulatory expenses |
|
0.04 |
|
|
— |
|
|
0.04 |
|
|
— |
|
||||
Management severance costs |
|
0.02 |
|
|
— |
|
|
0.02 |
|
|
— |
|
||||
Executives transition costs |
|
— |
|
|
— |
|
|
— |
|
|
0.05 |
|
||||
Severance-related expenses, net of reversals |
|
— |
|
|
0.22 |
|
|
— |
|
|
0.34 |
|
||||
Amortization of debt issuance costs |
|
0.02 |
|
|
0.03 |
|
|
0.08 |
|
|
0.10 |
|
||||
Gain on extinguishment of convertible senior notes, net |
|
(0.16 |
) |
|
— |
|
|
(0.16 |
) |
|
— |
|
||||
Tax effect of the adjustments above (b) |
|
(0.02 |
) |
|
(0.10 |
) |
|
(0.16 |
) |
|
(0.30 |
) |
||||
Non-GAAP net income per share - diluted |
$ |
0.60 |
|
$ |
0.33 |
|
$ |
1.71 |
|
$ |
1.91 |
|
||||
|
|
|
|
|
||||||||||||
Omnicell, Inc. |
||||||||||||||||
Reconciliation of GAAP to Non-GAAP |
||||||||||||||||
(Unaudited, in thousands, except per share data and percentage) |
||||||||||||||||
|
|
|
|
|
||||||||||||
|
|
Three Months Ended
|
|
Year Ended
|
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Reconciliation of GAAP net income (loss) to non-GAAP EBITDA (c): |
||||||||||||||||
GAAP net income (loss) |
$ |
15,842 |
|
$ |
(14,375 |
) |
$ |
12,531 |
|
$ |
(20,371 |
) |
||||
Share-based compensation expense |
|
9,039 |
|
|
12,187 |
|
|
39,316 |
|
|
55,300 |
|
||||
Interest (income) and expense, net |
|
(5,062 |
) |
|
(5,811 |
) |
|
(23,399 |
) |
|
(18,542 |
) |
||||
Depreciation and amortization expense |
|
19,966 |
|
|
21,723 |
|
|
82,232 |
|
|
87,319 |
|
||||
Acquisition-related expenses |
|
182 |
|
|
244 |
|
|
898 |
|
|
982 |
|
||||
Impairment and abandonment of operating lease right-of-use and other assets related to facilities (a) |
|
— |
|
|
1,587 |
|
|
— |
|
|
10,007 |
|
||||
RDS restructuring, net of reversals |
|
2,434 |
|
|
1,610 |
|
|
11,953 |
|
|
1,610 |
|
||||
Ransomware-related insurance recoveries |
|
— |
|
|
(624 |
) |
|
— |
|
|
(808 |
) |
||||
Legal and regulatory expenses |
|
2,000 |
|
|
— |
|
|
2,000 |
|
|
— |
|
||||
Management severance costs |
|
911 |
|
|
— |
|
|
911 |
|
|
— |
|
||||
Executives transition costs |
|
— |
|
|
— |
|
|
— |
|
|
2,189 |
|
||||
Severance-related expenses, net of reversals |
|
— |
|
|
10,085 |
|
|
— |
|
|
15,539 |
|
||||
Amortization of debt issuance costs |
|
871 |
|
|
1,258 |
|
|
3,788 |
|
|
4,397 |
|
||||
Gain on extinguishment of convertible senior notes, net |
|
(7,517 |
) |
|
— |
|
|
(7,517 |
) |
|
— |
|
||||
Provision for (benefit from) income taxes |
|
7,758 |
|
|
(4,142 |
) |
|
13,062 |
|
|
263 |
|
||||
Non-GAAP EBITDA |
$ |
46,424 |
|
$ |
23,742 |
|
$ |
135,775 |
|
$ |
137,885 |
|
||||
Non-GAAP EBITDA margin (non-GAAP EBITDA as a % of total revenues) |
|
15.1 |
% |
|
9.2 |
% |
|
12.2 |
% |
|
12.0 |
% |
||||
|
|
|
|
|
||||||||||||
Reconciliation of GAAP net cash provided by operating activities to non-GAAP free cash flow: |
||||||||||||||||
GAAP net cash provided by operating activities |
$ |
56,315 |
|
$ |
38,414 |
|
$ |
187,722 |
|
$ |
181,094 |
|
||||
External-use software development costs |
|
(4,481 |
) |
|
(3,302 |
) |
|
(16,330 |
) |
|
(13,542 |
) |
||||
Purchases of property and equipment |
|
(9,087 |
) |
|
(9,070 |
) |
|
(36,463 |
) |
|
(41,474 |
) |
||||
Non-GAAP free cash flow |
$ |
42,747 |
|
$ |
26,042 |
|
$ |
134,929 |
|
$ |
126,078 |
|
||||
| ____________________________ | ||
(a) |
For the year ended December 31, 2023, impairment charges of other assets were approximately |
|
(b) |
Tax effects calculated for all adjustments except share-based compensation expense, using an estimated annual effective tax rate of |
|
(c) |
Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20250206336508/en/
Kathleen Nemeth
Senior Vice President, Investor Relations
650-435-3318
Kathleen.Nemeth@Omnicell.com
Source: Omnicell, Inc.
FAQ
What were Omnicell's (OMCL) Q4 2024 revenue and earnings results?
How much did OMCL's total bookings grow in 2024?
What is Omnicell's (OMCL) revenue guidance for 2025?
What was OMCL's cash position at the end of 2024?
What new debt did OMCL issue in late 2024?
